tag:blogger.com,1999:blog-7857054149675424609.post7443136416175278857..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: ISIS Demonstrates Wider Utility of RNaseH ASOs for Nuclear TargetsDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-80193671601688454302013-12-19T20:49:28.400+00:002013-12-19T20:49:28.400+00:00OK, let's just ignore the title. Are you serio...OK, let's just ignore the title. Are you serious? The title is the major issue with the paper. It is simply WRONG and very conveniently misleading.<br /><br />So after asking me to ignore the elephant in the room, you are inviting me to splitting hairs with you? Oh yes, somewhere for some gene ISIS has shown some type of mediocre knockdown at therapeutically irrelevant doses? <br /><br Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-35633386149945510392013-12-18T21:22:01.127+00:002013-12-18T21:22:01.127+00:00Wording of the paper title aside....
If I underst...Wording of the paper title aside....<br /><br />If I understand correctly, you are also saying that...<br /><br />* Isis has ONLY reported sufficient (i.e., 50% or greater) knock down of a nuclear retained target RNA (e.g., MALAT1) in muscle with either the MOE or Gen 2.5 chemistry in a preclinical research model, but alternatively...<br /><br />* has not reported the same extent of knock down Anonymousnoreply@blogger.com